ADMA Biologics, Inc. Financials

Market Capitalization $3.92 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	61.41
Forward PE	23.03
Price to Sales TTM	$10.24
Price to Book MRQ	$16.90
Enterprise to Revenue	10.30
Enterprise to EBITDA	31.33

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	17.80%
Operating Margin	33.08%
Return on Assets TTM	19.89%
Return on Equity TTM	35.55%

Income Statement

Revenue TTM	$382,808,992
Revenue per Share TTM	$1.66
Quarterly Revenue Growth	78.10%
Gross Profit TTM	$189,406,000
EBITDA	$125,006,273
Net Income to Common TTM	$68,132,000
Diluted EPS TTM	$0.27
Quarterly Earnings Growth YoY	1300.00%

Balance Sheet

Total Cash MRQ	$86,707,000
Total Cash per Share MRQ	$0.37
Total Debt MRQ	$
Total Debt to Equity MRQ	48.03
Current Ratio MRQ	7.09
Book Value per Share MRQ	$0.98

Cash Flow

Operating Cash Flow TTM	$86,053,000
Levered Free Cash Flow TTM	$45,999,108

ADMA Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	236,390,000
Float Shares	232,104,498
Avg 10 Volume	2,635,680
Avg 30 Volume	None
Shares Short	13,622,817
Short Ratio	5.50
Short % of Shares	5.93%
% Held by Insiders	2.50%
% Held by Institutions	91.36%

Stock Price Summary

Beta	0.65
Fifty Two Week Low	$5.02
Fifty Two Week High	$23.64
Fifty Two Week Change	66.85%
Day 50 MA	$18.97
Day 200 MA	$14.69

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date